Epigenomic biomarkers insights in PBMCs for prognostic assessment of ECMO-treated cardiogenic shock patients

Yi-Jing Hsiao,Su-Chien Chiang,Chih-Hsien Wang,Nai-Hsin Chi,Hsi-Yu Yu,Tsai-Hsia Hong,Hsuan-Yu Chen,Chien-Yu Lin,Shuenn-Wen Kuo,Kang-Yi Su,Wen-Je Ko,Li-Ming Hsu,Chih-An Lin,Chiou-Ling Cheng,Yan-Ming Chen,Yih-Sharng Chen,Sung-Liang Yu
DOI: https://doi.org/10.1186/s13148-024-01751-6
2024-10-04
Clinical Epigenetics
Abstract:As the global use of extracorporeal membrane oxygenation (ECMO) treatment increases, survival rates have not correspondingly improved, emphasizing the need for refined patient selection to optimize resource allocation. Currently, prognostic markers at the molecular level are limited.
oncology,genetics & heredity
What problem does this paper attempt to address?